Androbalance SelenoExcell® 200ug x 90 capsules

< back to product list

Androbalance SelenoExcell® is a virtually pure encapsulation of Cypress System's SelenoExcell® High Selenium Yeast. The only excipient added is stoneground brown rice flour as a bulking agent. The product is presented in vegetable cellulose capsules, each providing 200ug of 100% organically bound selenium for convenient once daily dosing.

SelenoExcell® is primary grown bakers yeast, cultured under stringently controlled conditions to optimise incorporation of inorganic selenium into organic selenium compounds. This replicates the biological incorporation of selenium by natural food sources, producing a heterogeneous blend of highly bio-available seleno-proteins, seleno-amino acids, seleno-lipids, and seleno-polysaccharides. This rich mixture of organic selenium compounds may be required to derive the full benefits of selenium supplementation, as evidenced by SelenoExcell® 's pre-eminent position as the product of choice for clinical trials and research studies.

SelenoExcell® 's Research History:

SelenoExcell® is the exact product used in Dr. Larry Clark's landmark Nutritional Prevention of Cancer (NPC) trial (265). This double blind placebo controlled trial found that compared to placebo, the 200ug selenium yeast group experienced:

NPC trial secondary end-point	Reduction observed in selenium treatment group in NPC trial
Total cancer mortality	↓50%*
Total cancer incidence	↓37%*
Lung cancer incidence	↓46%*
Colorectal cancer incidence	↓58%*
Prostate cancer incidence	↓63%*

Data drawn from reference (265).

*Statistically significant reductions (P = .04 or better)

These remarkable results, and Cypress's exacting production standards, satisfied the US National Cancer Institute's (NCI) stringent requirements and secured a clinical trial agreement for SelenoExcell®. SelenoExcell® was subsequently approved as the product of choice for the NPC trial extension, and selected for numerous additional clinical trials. Furthermore, the large multi-centre Prevention of Cancer by Intervention with Selenium (PRECISE) trial, used products developed from SelenoExcell®.

Continued cohort analysis through the unblinded NPC trial extension substantiated the initial findings:

NPC trial secondary end-point	Reduction observed in selenium treatment group in full NPC analysis (1983-1996) including unblinded phase
Total cancer mortality	↓41%*
Total cancer incidence	↓25%*
Lung cancer incidence	↓30%♦
Colorectal cancer incidence	↓54%
Prostate cancer incidence	↓49%*

Data drawn from references (266,267,268)	* Statistically significant reductions (P = .03 or better)
♦ Though not significant for total cohort, a significant reduction in lung cancer was observed for subjects in the lowest two tertiles of serum selenium at trial entry.

Significant risk reductions were found only for males in the lower two tertiles of serum selenium at trial entry (266,267,268). Unsupplemented UK and European males lie within these tertiles and so may benefit from supplementation (269,270,271 & Table 2 below).

UK and European Diets are Selenium Deficient:

Unsupplemented UK and European diets are selenium deficient (269,270,271,272,273,274,275,280). Not only do they fail to meet the UK's own Reference Nutrient Intake (RNI) of 75 ug per day (269,270,271,272,273,274,275), but this RNI is itself insufficient for optimal expression of the selenium-dependant glutathione peroxidase antioxidant enzymes (269,270,271,272,273,276,277,278).

Furthermore, UK selenium intake has fallen by 35-40% over the past three decades (269,270,271,274), largely as a result of switching to selenium poor European wheat instead of selenium rich Canadian imports (275,279).

*RNI for average person, based on 1 ug/kg body weight(272).
Table 1 drawn from data presented in reference(274).

Supra-Nutritional Levels of Selenium May Confer Additional Benefit:

The NPC trial was conducted in the US, where selenium intakes are generally higher than the UK (270,271,280). At entry, most NPC subjects already had maximal glutathione peroxidase expression, yet still benefited from supplementation (265,266,267,268,270,271,280,281).

Thus, supra-nutritional selenium levels beyond those required for maximisation of glutathione peroxidase may confer additional health benefits (270,271,273,280,282,283,285,298,299), possibly by enhancing production of cancer fighting selenium metabolites (271,280,282,283,284,285), by stimulating anti-tumorigenic elements of the immune system (282,298,300), and/or by other mechanisms (282,283,284,285).

These points are illustrated below, along with the target serum selenium level suggested as the optimum for minimisation of cancer risk (280). These serum levels are attainable with once per day dosing of SelenoExcell® (265,281).

* From references(265,281)
+ From reference(280)
~ From references(276,277,278,270,271,273)
Table 2 drawn from data presented in references(268,273)

Average UK residents have serum selenium levels within the lowest tertile in the NPC trial (269,270,271,281), the tertile that received the strongest benefit from supplementation (266,267,268,281). They may therefore derive similar benefits to those observed in the NPC study (270,271). Recent evidence suggesting poor selenium bio-availability from some animal sources (286) may strengthen the case for supplementation.

Potential Benefits of Selenium Supplementation:

• Solid evidence for cancer prevention, as supported by a wealth of epidemiological studies, laboratory investigations, and clinical intervention trials (265,266,267,268,270,271,281,282,283,284,285,287,288,289,290,291,292,293,294,300).
• Enhanced immunity (270,271,295,296,297,298,299,300) even in 'Se replete' individuals (298,299).
• Enhanced conversion of T4 to active T3 (278,301). This conversion can be compromised by selenium deficiency (270,271) as the enzymes responsible are selenium dependant (302,303,304).
• Reduced viral pathogenicity. In selenium deficient hosts pathogenic viruses can become even more virulent and benign strains can become pathogenic (305,306,307,308). Selenium deficiency facilitates these mutations (305,306,307,308) and may promote emergence of new viral diseases such as HIV which arose in selenium deficient areas of Zaire, and new influenza strains which often arise in selenium deficient belts in China (270,271,309,310).
• Improved health status in HIV (311,312,313). Selenium deficiency increases HIV related mortality more than ten-fold (314), and disease progression is positively correlated with falling selenium levels (314,315,316).
• Reduced progression of hepatitis B to liver cancer (317).
• Enhanced fertility (318). A selenoprotein is essential for structural integrity and motility of sperm (319, 320,321) and deficiency impairs sperm morphology, motility and fertility (318,320,321).
• Improved mood (322,323,324,325,326) and potential protection of brain function (327,328).
• Cardiovascular benefits (270,271,329,330).
• Improvements in pancreatitis (331,332,333), asthma (334,335,336), and other oxidative stress conditions (270,271).
• Reduced mercury load in the body (337).

Warning:

Do not exceed the stated dose. Selenium has a narrow therapeutic window and high intakes can be toxic (282). Moreover, the putative chemopreventive effects may be negated at higher intakes (266,267,268).

£7.99